

Index

A

- ABA. *See* Applied behavior analysis
- ADHD. *See* Attention-Deficit/Hyperactivity Disorder
- ADOS. *See* Autism Diagnostic Observation Schedule
- Adult-directed teaching, 149–150
- Affection, 40
- AIT. *See* Auditory Integration Training
- Alternative therapies: and Auditory Integration Training (AIT), 135–136; and Facilitated Communication (FC), 136. *See also* Complementary and alternative medicine
- Amazon.com, 1
- American Academy of Child and Adolescent Psychiatry, 136
- American Academy of Neurology, 66
- American Academy of Pediatrics, 66, 136
- American Association on Mental Retardation, 136
- American Psychiatric Association, 185
- American Psychological Association, 136
- American Speech-Language-Hearing Association, 136
- Applied behavior analysis (ABA), 119–120
- Ascorbic acid (Vitamin C), 132
- Asperger, H., 7
- Asperger's Disorder, 1–2, 7–8, 11
- Attention-Deficit/Hyperactivity Disorder (ADHD), 21, 60, 113
- Auditory Integration Training (AIT), 135–136
- Augmentative and alternative communication therapy (AAC) approaches, 114–115
- Autism: cause of, 20–22; common symptoms of, 11–19; genetics and, 21; and impaired language and communication skills, 13–15; and impaired social skills, 12–13; importance of early detection and intervention in, 22–23; and restricted interests and repetitive activities, 15–19; and siblings, 25; *versus* speech delay, 24–25
- Autism and PDD Support Network, 75
- “Autism and the MMR Vaccine” (National Institute of Child Health and Human Development), 23
- Autism, diagnosis of: accuracy of early, 31–32; and challenges of early detection, 34–40; and early signs, 29–31; frequently asked questions about, 60–62; importance of early, 28–34; reasons for early, 32–34
- Autism Diagnostic Interview-Revised, 80
- Autism Diagnostic Observation Schedule (ADOS), 85–87
- Autism Society of America, 4, 75, 76, 92, 142

Autism Spectrum Disorders (ASDs): and Asperger's Disorder, 7–8; and Autistic Disorder, 7; and Childhood Disintegrative Disorder (CDD), 8–9; definition of, 1–2, 5–7; and Rett's Disorder, 8; understanding different, 5–9

Autistic Disorder, 1–2, 7, 31; diagnosis of, 92; diagnostic criteria for, 185–186; focusing on, 9–11; *versus* PDDNOS, 91

B

Baby Siblings Research Consortium, 82

Baron-Cohen, S., 60

Barton, M., 187

Bayley Scales of Infant Development-II, 81–83

Behaviors: intervention, 119–120; restricted and repetitive, 49–50; stereotyped, 97–99, 132

Berard, G., 135

Biological agents, 134–135

Boardmaker software (Mayer-Johnson), 153

Brand-name programs: and Developmental, Individual-Difference, Relationship-Based Model (DIR), 127–128; and Early Intensive Behavior Intervention (EIBI), 128; overview, 121–127; and “Questions to Ask About Autism Treatment” form, 124–126 *Fig. 4.1*; and Relationship Development Intervention (RDI), 128; and structured teaching, 129

C

CAM. *See* Complementary and alternative medicine

Cambridge University, 60

CARS. *See* Childhood Autism Rating Scale

Casein, 133

Centers for Disease Control and Prevention, 4, 29

Cerebral palsy, 29

Chelation/Heavy Metal Detoxification, 134

Child-directed teaching, 150–151

Childhood Autism Rating Scale (CARS), 87, 88

Childhood Disintegrative Disorder (CDD), 1–2, 8–9, 11, 186

Choices, 162–164

Clinic for Behavioral Treatment of Children (UCLA), 119

Clinical trials, 98

Cod liver oil, 132

Cognitive and developmental evaluation, 70

Cognitive testing, 81–85

Collaborative Programs of Excellence in Autism (CPEA), 98

Communication skills: in diagnostic evaluation, 86–87; and false leads, 35; and functional communication, 161–171; impaired, 13–15; impaired language and, 45–50

Complementary and alternative medicine (CAM): and biological agents, 134–135; and dietary supplements, 131–133; and elimination diets, 133; overview, 129–131; research on, 142; and secretin therapy, 135. *See also* Alternative therapies

Conference, interpretive. *See* Interpretive conference

Congenital rubella, 20

Courchesne, E., 82

CPEA. *See* Collaborative Programs of Excellence in Autism

Crying, 13

Cure Autism Now (CAN), 98

Cystic fibrosis, 20

Cytomegalovirus, 20

D

Detection, early. *See* Early detection

Developmental, Individual-Difference, Relationship-Based model (DIR), 127–128

Developmental preschool, 117–118

Diagnoses: and interpretive conference, 88–91; of “not autism,” 91; of PDDNOS, 91–92; receiving, of autism, 92; talking to other children about, 93–94; talking to parents about, 94–95

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV), 5, 7, 34, 35, 73, 97

Diagnostic evaluation, 70
 Dietary supplements, 131–133
 Dimercaptosuccinic acid (DMSA), 134
 Dimethylglycine (DMG), 132–133
 DIR. *See* Developmental, Individual-Difference, Relationship-Based model
 Discrete trial training, 119
 DMG. *See* Dimethylglycine
 DMSA. *See* Dimercaptosuccinic acid
 Doctor, family. *See* Physician
 Down syndrome, 20
 Dyslexia, 60

E

Early detection, 22–23; case of (Luke), 50–52, 96–97, 141–144, 177–178; challenges of, 34; complexity of disrupted symptoms in, 38–40; dos and don'ts of, 40; and false leads, 35–37; and hidden symptoms, 37–38
 Early diagnosis process: and approaching child's doctor, 64–73; cognitive testing in, 81–85; and diagnosis of Autistic Disorder, 92; and diagnosis of “not autism,” 91; and diagnosis of PDDNOS, 91; frequently asked questions in, 97–99; and interpretive conference, 88–91; and observing child's behavior, 85–88; and talking to your parents about diagnosis of autism, 94–95; and telling family members news, 92–95; and telling your other children of the diagnosis, 93–94; and using Parent Observation Checklist, 65–66; what to expect in, 77–80
 Early Intensive Behavior Intervention (EIBI), 128
 Early intervention, 22–23; and “brand name” programs, 121–129; and Developmental, Individual-Difference, Relationship-Based Model (DIR), 127–128; and Early Intensive Behavior Intervention (EIBI), 127–128; and Individual Family Service Plan (IFSP), 109–113; and more restricted play patterns, 106–107; obtaining services in, 107–113; parents on, 101, 122; and questions to ask about autism treatments, 124–126; and Relationship Development

Intervention (RDI), 127–128; and structured teaching, 129; types of, services, 113–121; and understanding child's learning style, 102–107
 Early intervention services: and behavioral intervention, 119–120; and developmental preschool, 117–118; and occupational therapy (OT), 115–116; and parent training, 120–121; and physical therapy (PT), 116–117; and speech-language therapy, 114–115. *See also* Brand-name programs; Complementary and alternative treatment

Echinacea, 137

EIBI. *See* Early Intensive Behavior Intervention

Elimination diets, 133

Emotional expression, 86

Evaluations: behaviors to observe during, 86–87; examples of professional, 70; getting most out of diagnostic, 73–77; obtaining medical, 69–71; parents, on asking for, 74, 79–80; red flags for immediate, 66; summary of steps to ensure proper, 76–77

F

“FAQs About MMR Vaccine and Autism” (National Immunization Program), 23

Fatty acids, 133

FC. *See* Functional communication

Fein, D., 187

Floortime, 127–128

Food and Drug Administration, 132

Fragile X syndrome, 20

Functional communication, 161–171

G

Gamma-aminobutyric acid (GABA), 132

Gender bias, 60

Genetic and metabolic testing, 70, 71

Genetic causation, 8, 21

German measles, 21

Gesturing, 156–157

GF-CF diet. *See* Gluten-free and casein-free diet

Gluten, 133

Gluten-free and casein-free (GF-CF) diet, 133
 Google, 1
 Green, J., 187
 Greenspan, S., 127
 Group design studies, 139
 Gutstein, S., 128

H

Hearing evaluation, 70
 Hearing loss, 29
 Help, requesting, 167–168
 Herpes encephalitis, 20
 High-risk children, 34
 Home movies, 33–34
 Home therapy: frequently asked questions about, 179–180; teaching activities for, 157–177; teaching strategies for, 148–157

I

IFSP. *See* Individual Family Service Plan
 Imitation, promoting, 158–161
 Immune system abnormalities, link with, 98–99
 Incidental teaching, 119
 Individualized Family Service Plan (IFSP), 108–113, 121, 143, 144; and components of effective treatment program, 112–113; sample outcomes and action steps, 111
 Individualized Educational Plan (IEP), 108–109
 Individuals with Disabilities Education Act, 71
 Inflexibility, 39
 Interactive play, 171–175
 Interests, restricted, 15–19; examples of, 16
 Interpretive conference, 88–91
 Intervention studies, 98
 Intravenous Immunoglobulin (IV-IG), 134
 IV-IG. *See* Intravenous Immunoglobulin

J

Joint attention, 168–171
Journal of Autism and Developmental Disorders, 187

K

Kindergarten readiness skills, 106–107

L

Language development milestones, 46–47
 Language skills: in diagnostic evaluation, 86; and false leads, 35–37; impaired, 13–15; impaired, and communication, 45–50; and language comprehension, 105
 Leaky gut syndrome, 133
 Learning style, child's: and exceptional early learning, 102–103; and less language comprehension, 105; and less social motivation, 103–105; and more restricted play patterns, 105–107; understanding, 102–107
 Lovaas, I., 119, 128

M

Magnesium, 132
 Mayer-Johnson Company, 153
 M-CHAT. *See* Modified Checklist for Autism in Toddlers
 McMaster University (Ontario, Canada), 30
 Measles-mumps-rubella (MMR) vaccine, 20, 132
 Mental retardation, 29
 Mercury, 134
 Metropolitan Atlanta Developmental Disabilities Surveillance Program, 29
 Modeling, 156–157
 Modified Checklist for Autism in Toddlers (M-CHAT), 67–69, 77, 187–190; interpreting, 190; scoring, 190
 MRI, 70
 Mullen Scales of Early Learning, 81–83
 Multiple sclerosis, 134

N

NAAR. *See* National Alliance for Autism Research (NAAR)
 Nashville, Tennessee, 4, 76
 National Alliance for Autism Research (NAAR), 82, 98

National Center for Complementary and Alternative Medicine, 142
 National Immunization Program, 23
 National Institute of Child Health and Human Development (NICHD), 82, 98
 Neurological evaluation, 70, 71
 Neurobiology and Genetics of Autism: Collaborative Programs of Excellence in Autism (CPEA), 98
 Neurofibromatosis, 20
New York Times, 1
 NICHD. *See* National Institute of Child Health and Human Development (NICHD)

O

Occupational therapy (OT), 115–116
 Omega-3 fatty acids, 133
 Ontario, Canada, 30

P

Parent interview, 80–81
 Parent Observation Checklist, 52, 57–59, 77, 80; Luke's parent, 53–56; using, 65–66
 Parent reports, retrospective, 33
 PDDNOS. *See* Pervasive Developmental Disorder Not Otherwise Specified
 PECS. *See* Picture Exchange Communication Systems
 Pervasive Developmental Disorder Not Otherwise Specified (PDDNOS), 1–2, 11, 31; diagnosis of, 91
 Pervasive Developmental Disorder (PDDs), 5–7; characteristics of, 10
Table 1.1; focusing on, 9–11
Pervasive Developmental Disorders (PDD; DSM-IV), 5
 Pesticides, 21
 Pharmacological medication, 145
 Phenotype, 21
 Phenylketonuria, 20
 Physical therapy (PT), 116–117
 Physician: approaching child's, 64–73; and obtaining medical evaluations, 69–71; proactive, 66–72; and referral to state early intervention service program (EI), 71–72; and screening tools, 66–69; watch-and-wait, 72–73

Picture Exchange Communication Systems (PECS), 119, 145
 Pictures, dependence on, 144
 Pivotal response training, 119
 Placebo effect, 138–139
 Play: interactive, 171–175; skills with toys, 175–177; turn-taking, 172–173
 Preschool: developmental, 117–118; regular, 118–119
 Prompts, using, 156–157
 Prostaglandins, 133
 Pyridoxine. *See* Vitamin B₆

R

RDI. *See* Relationship Development Intervention
 Reciprocity, 44–45
 Red flags, for immediate evaluation, 66
 Regular preschool, 118–119
 Relating, 35–37
 Relationship Development Intervention (RDI), 128
 Repetitive activities, 15–19; examples of, 16; and false leads, 35–37
 Requesting, 161–168; help, 167–168; and initiating spontaneous requests, 165–167; joint attention, 168–171; and making choices, 162–164; more, 167
 Research, approaches to, 33–34; and alternative medicine, 142; and home movies, 33–34; and prospective studies of “high-risk” children, 34; and research today, 82; and retrospective parent reports, 33
 Rett, A., 8
 Rett's Disorder, 1–2, 8, 11, 186
 Rewards, 153–155
 Robins, D., 187

S

Schopler, E., 129
 Scientific method, 137–139
 Screening tools, 66–69; examples of, 68
Table 3.1
 Secretin therapy, 135
 Seizures, 61–62
 Sensitivity, extreme, 62
 Sensory integration therapy (SI), 115–116

- Serotonin, 132
- Siblings, 30
- Social interaction, 35–37, 41–45; in diagnostic evaluations, 86; impaired, and reciprocity, 41–45; and reciprocity, 41–45; skills, early, 171–172
- Social motivation, 103–105
- Social skills: impaired, 12–13; and lack of variety in behaviors, 39
- Speech, 13–14; delay, 24–25
- Speech-language communication evaluation, 70
- Spontaneous requests, 165–167
- State early intervention program, 71–72
- Structured teaching, 129
- Symptom expression, variability in, 18–19
Table 1.2
- Symptoms, children under three: and behaviors that occur less often in two-year-olds, 42 *Fig. 2.1*; and impaired language and communication, 45–50; impaired social interaction and reciprocity, 41–45; and restricted and repetitive behaviors, 49–50
- T**
- TEACCH. *See* Treatment and Education of Autistic and Related Communication Handicapped Children
- Teaching activities: overview, 157–158; to promote functional communication, 161–171; to promote functional play skills with toys, 175–177; to promote imitation, 158–161; to promote interactive play, 171–175
- Teaching strategies: adult-directed, 149–150; child-directed, 150–151; and combining different methods, 149–153; and identifying and using rewards, 153–155; overview, 147–149; and using prompts, 156–157; and visual supports, 151–153
- Testosterone, 60
- Thimerosal, 20, 134
- Total communication approach, 114
- Treatment and Education of Autistic and Related Communication Handicapped Children (TEACCH), 129
- Treatment evaluation: cautious approach in, 139–141; quick elimination list for, 141; scientific method for, 137–139
- TRIAD clinic (Nashville, Tennessee), 4, 157
- U**
- United States Centers for Disease Control and Prevention (CDC), 23
- University of California, Los Angeles, 119
- University of California, San Diego, 82
- University of North Carolina, 129
- V**
- Vaccines, 23
- Vanderbilt Children's Hospital (Nashville, Tennessee), 4, 115, 158
- Vanderbilt Kennedy Center (Nashville, Tennessee), 4
- Videotapes, 33
- Vineland Adaptive Behavior Scales, 81
- Vision impairment, 29
- Visual supports, 151–153
- Vitamin A, 132
- Vitamin B₆, 132
- Vitamin C, 132
- W**
- Wieder, S., 127
- Z**
- Zwaigenbaum, L., 30